#United States #New York #Pomerantz LLP #Soleno Therapeutics #SLNO

Investor Alert: Pomerantz Law Firm Investigates Claims on Behalf of Soleno Therapeutics Investors

Pomerantz LLP, a leading global law firm renowned for handling corporate, securities, and antitrust class action lawsuits, has initiated an investigation on behalf of investors in Soleno Therapeutics, Inc. (NASDAQ: SLNO). This inquiry follows serious allegations that point towards potential securities fraud or other illicit business maneuvers carried out by Soleno and its executives.

On August 15, 2025, Scorpion Capital released a contentious report labeling Soleno’s sole product, Vykat XR, as excessively priced and possibly hazardous for pediatric use. The implications of such accusations have already had a significant impact, with Soleno's stock plummeting by $5.73 per share—a staggering 7.41%—to close at $71.63 that same day.

The fallout from Scorpion's claims raises critical questions regarding the integrity of Soleno's marketing strategies and product safety standards, particularly as they relate to vulnerable populations like children. Investors who believe they may have been harmed by these developments are urged to come forward and seek guidance.

Investors are invited to contact Danielle Peyton at Pomerantz LLP for further information and assistance regarding their rights. The firm is particularly dedicated to seeking restitution for individuals adversely affected by misleading corporate conduct.

Founded over 85 years ago by Abraham L. Pomerantz, recognized as the 'dean of the class action bar', Pomerantz has established a formidable reputation in the field of securities class action litigation. The firm has successfully recovered substantial compensations for victims of corporate fraud and unethical practices in the marketplace.

For those keen on joining the class action lawsuit against Soleno, further details can be accessed via direct contact to the firm or their official website. Pomerantz remains committed to its legacy of advocating for justice and protecting investors’ interests against corporate misconduct.

If you are an investor in Soleno Therapeutics or have concerns related to your investment, do not hesitate to reach out to the contact provided below for assistance in navigating these developments.

Contact Information

Danielle Peyton
Pomerantz LLP
Email: [email protected]
Phone: 646-581-9980, ext. 7980

The investigation by Pomerantz LLP serves as a crucial step for investors seeking accountability from Soleno Therapeutics amidst troubling allegations. Interested individuals are encouraged not to delay in reaching out to understand their options better and ensure they are represented adequately in the unfolding situation.